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Patients with 3q21q26 rearrangements seem to share similar clinicopathologic features and a common molecular mechanism,
leading to myelodysplasia or acute myeloid leukemia (AML). The ectopic expression of EVI1 (3q26) has been implicated in the
dysplasia that characterizes this subset of myeloid neoplasias. However, lack of EVI1 expression has been reported in several
cases, and overexpression of EVI1 was detected in 9% of AML cases without 3q26 abnormalities. We report the molecular
characterization of seven patients with inv(3)(q21q26), t(3;3)(q21;q26) or related abnormalities. EVI1 expression was detected
in only one case, and thus ectopic expression of this gene failed to explain all of these cases. GATA2 (3q21) was found to be
overexpressed in 5 of the 7 patients. GATA2 is highly expressed in stem cells, and its expression dramatically decreases when
erythroid and megakaryocytic differentiation proceeds. No mutations in GATA1 were found in any patient, excluding loss of
function of GATA1 as the cause of GATA2 overexpression. We report finding molecular heterogeneity in patients with 3q21q26
rearrangements in both breakpoints and in the expression pattern of the genes near these breakpoints. Our data suggest that
a unique mechanism is not likely to be involved in 3q21q26 rearrangements. © 2004 Wiley-Liss, Inc.
INTRODUCTION
Rearrangements of the long arm of chromosome
3, namely, the inv(3)(q21q26) and the t(3;3)(q21;
q26), are found in approximately 2.5% of patients
with acute myeloid leukemia (AML) and have also
been observed in some cases with myelodysplastic
syndrome (MDS) and in the megakaryoblastic cri-
sis of chronic myeloid leukemia (CML). Patients
with these karyotypes share clinical features, in-
cluding multilineage involvement, in particular,
erythroid and megakaryocytic dysplasia, with mi-
cromegakaryocytes that have hypolobulated nuclei,
an elevated or normal (instead of low) platelet
count, poor prognosis, with minimal or no response
to chemotherapy, and a short survival (Bitter et al.,
1985; Jenkins et al., 1989; Lee et al., 1990; Jotter-
and Bellomo et al., 1992; Grigg et al., 1993; Fon-
atsch et al., 1994; Secker-Walker et al., 1995; Shi et
al., 1997; Testoni et al., 1999; Reiter et al., 2000).
The chromosomal breakpoints (BPs) in 3q26 are
scattered over several hundred kilobases (kb) ei-
ther in the 5 or the 3 region of the EVI1 gene
(Morishita et al., 1992; Levy et al., 1994; Suzukawa
et al., 1994). In the 3q21 region, the BPs appears to
be restricted to a much smaller genomic region,
and two different clusters that account for around
100 kb have been defined downstream of the RPN1
gene (Wieser et al., 2000a). The leukemogenic
mechanism in the 3q21q26 rearrangement has
been suggested to be the ectopic expression of the
EVI1 gene by the housekeeping gene RPN1 acting
as an enhancer of EVI1 expression (Suzukawa et
al., 1994). This molecular mechanism, which has
been described mainly in lymphoid leukemias and
lymphomas, is an uncommon mechanism in my-
eloid leukemias, although some examples have
been reported (Vinatzer et al., 2001; Cools et al.,
2002).
The EVI1 protooncogene codes for a DNA bind-
ing zinc finger protein that may act as a repressor or
activator of transcription (Morishita et al., 1988;
Kreider et al., 1993; Bartholomew et al., 1997; Kil-
bey et al., 1998). Alternative splicing of EVI1 gives
rise to the MDS1/EVI1 transcript by fusion with
MDS1, a four-exon gene upstream and telomeric to
EVI1 with an unknown function that is also ex-
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pressed by itself. The protein encoded by MDS1/
EVI1 is identical to EVI1 except for an N-terminal
extension of 188 amino acids that has 40% homol-
ogy to the PR domain also present in the tumor
suppressor retinoblastoma-binding protein RIZ1,
another member of the PR domain family along
with MDS1/EVI1 (Fears et al., 1996). The PR
domain is encoded in part by MDS1 and in part by
an open reading frame in exons 2 and 3 of EVI1
mRNA, which precedes the EVI1 ATG start codon
(Fears et al., 1996). Barjesteh van Waalwijk van
Doorn-Khosrovani et al. (2003) reported an analysis
that was the first to discriminate among the expres-
sion of MDS1, MDS1/EVI1, and EVI1 by real-time
quantitative polymerase chain reaction (PCR). All
eight patients analyzed, who had the classical t(3;3)
or inv(3), showed EVI1 expression, but expression
of MDS1/EVI1 was also detected in seven patients.
Vinatzer et al. (2003) analyzed the expression of
MDS1/EVI1 and cEVI1, a region common to EVI1
and MDS1/EVI1. Thirteen patients analyzed with
inv(3) or t(3;3) showed high expression of cEVI1, in
10 of whom MDS1/EVI1 expression also was high,
leading to the conclusion that MDS1/EVI1 overex-
pression does not prevent the emergence of leuke-
mia.
Although the exact mechanism of transformation
by EVI1 is obscure, several studies have shown that
ectopic expression of this gene in immature hema-
topoietic cells interferes with erythroid and granu-
locytic development (Kreider et al., 1993). It is
generally accepted that EVI1 is inappropriately ex-
pressed in leukemia cells after rearrangements of
the 3q26 chromosome band; however, Barjesteh
van Waalwijk van Doorn-Khosrovani et al. (2003)
and Zoccola et al. (2003) found EVI1 overexpres-
sion in 9% (28 of 315) and 20.6% (7 of 34) of AML
and myeloid neoplasias without 3q26 rearrange-
ments, respectively. Moreover, Barjesteh van
Waalwijk van Doorn-Khosrovani et al. (2003) also
showed that only 12.5% (4 of 32) of the patients
that overexpressed EVI1 carried a 3q26 abnormal-
ity and that EVI1 expression is a poor prognosis
marker. It was found that in several cases with
3q21q26, EVI1 was not expressed (Fichelson et al.,
1992; Morishita et al., 1992; Soderholm et al., 1997;
Langabeer et al., 2001). Thus, ectopic expression
of EVI1 is a mechanism that fails to explain the
characteristics of all patients with 3q21q26 rear-
rangements (Wieser, 2002).
Several chimeric gene fusions involving MDS1/
EVI1 and EVI1 have been described in cases with
t(3;21)(q26;q22) and t(3;12)(q26;p13) (Nucifora et
al., 1994; Peeters et al., 1997). However, the BPs in
the 3q21q26 rearrangements usually occurred out-
side the genes. Fusion transcripts involving EVI1
with RPN1 have been reported in 9 patients with
AML and either inv(3) or t(3;3) (Martinelli et al.,
2003) and in the USCD-AML1 cell line, which
carries a t(3;3) (Pekarsky et al., 1997). This cell line
also carried the only fusion transcript involving
EVI1 with GR6 described to date (Pekarsky et al.,
1997).
Here, we report the molecular characterization of
seven patients with inv(3)(q21q26) or t(3;3)(q21;
q26). A wide heterogeneity in both of the BPs in
these regions and in the expression pattern of the
genes near the BPs was found. This study confirms
that ectopic expression of EVI1 fails to explain all
cases with 3q21q26 rearrangements. In addition,
GATA2, a gene in the breakpoint cluster region of
3q21, was overexpressed in 83% of cases, suggest-
ing a role for this gene in a more complex mecha-
nism involved in the development of 3q21q26 re-
arrangements.
MATERIALS AND METHODS
Case Reports
Seven patients with myeloid neoplasias and
inv(3)(q21q26) (5 cases) or t(3;3)(q21;q26) (2 cases)
studied at the University of Navarra (Spain) and at
the University of Siena (Italy) were included in the
present investigation. Five had AML de novo, and
two had MDS. Clinical data are shown in Table 1.
All samples were obtained with informed consent.
G-Banding Karyotype
Cytogenetic studies were done on unstimulated
short-term bone marrow (BM) cultures. G-banded
karyotypes, described according to the ISCN
(Mitelman, 1995), are shown in Table 1.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) stud-
ies were performed by use of eight BACs and one
PAC located in 3q21 and 3q26. The order of the
probes according to the current mapping data is:
centromere—RP11 202D20—RP11 390G14—
RP11 525K18—RP3 519C2—RP11 475N22—
RP11 689D3—RP11 221E20—RP11 82C9—
RP-11 115B16—telomere. The clones were
obtained from the Roswell Park Cancer Institute
(Buffalo, NY). Information about these probes, in-
cluding their relative physical positions and the
genes the probes cover, is shown in Figure 1A. The
probes were labeled with SpectrumGreen and
SpectrumOrange (Vysis, Downers Grove, IL) by
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nick translation and used pairwise. A commercial
probe for BCL6 also was used (Vysis). FISH anal-
ysis was performed on BM samples as previously
described (Odero et al., 2001).
Nucleic Acid Isolation
The RNeasy Mini Kit (Qiagen, Hilden, Ger-
many) was used to extract total RNA from frozen
cell pellets from BM of the patients, and from BM
and peripheral blood (PB) from healthy donors.
CD34 cell isolation was performed from mononu-
clear cells of normal BM using the Direct CD34
Progenitor cell isolation kit (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). Genomic DNA was
obtained with the QIAamp DNA Mini Kit (Qia-
gen) from fixed cells of the patients and from BM
and PB from healthy donors. DNA from BAC and
PAC clones was extracted by use of a Qiaprep
Spin Miniprep kit (Qiagen).
Reverse Transcriptase-PCR
Total RNA (1 g) was used for cDNA synthesis
with SuperScript™ II RNase H RT (Invitrogen
Life Technologies, Paisley, UK) that had random
hexamers. RT-PCR amplification was performed
under standard conditions with AmpliTaq Gold
DNA polymerase (Applied Biosystems, Foster
City, CA), with 35 cycles at the annealing temper-
ature (AT) shown below in parentheses for each
pair of primers. Primers were designed for specific
assays of amplification for EVI1 (EVI1-F and EVI1-
MDS1/EVI1-R; AT: 57°C), MDS1/EVI1 (MDS1/
EVI1-F and EVI1-MDS1/EVI1-R; AT: 57°C),
MDS1 (MDS1-F and MDS1-R; AT: 53°C), GR6
(GR6-F and GR6-R; AT: 64°C) and GATA2
(GATA2-F and GATA2-R; AT: 60°C). All reac-
tions were carried out on cDNA from BM of the
patients and on BM, PB, and CD34 cells from
healthy donors. The primers used for analyzing the
three possible intergenic transcripts (ITs) de-
scribed by Pekarsky et al. (1997) between GR6 and
EVI1 were IT1: GR6-1-F and EVI1-2A-R (AT:
59°C); IT2 and its variant, IT3: GR6-4-F and
EVI1-2A-R (AT: 61°C); and the possible fusion
transcript between RPN1-EVI1 IT4: RPN1-1-F
and EVI1-2B-R (AT: 62°C). All reactions were car-
ried out on BM from the patients and from a
healthy donor. BCR amplification was performed as
a control for the quality of the cDNA used, with
primers BCR-F and BCR-R under standard condi-
tions, an AT of 55°C, and 35 cycles. The sequence
of the primers is shown in Table 2.
Semiquantitative RT-PCR
Expression levels of GATA2 were compared in
BM cells of case 7 and in a healthy donor by
semiquantitative RT-PCR, using GATA2-F and
GATA2-R primers for GATA2 and BCR-F and
BCR-R primers for BCR. The BCR gene was used
as an internal control. Serial dilutions of both sam-
ples were analyzed to assure that all reactions were
kept in the linear phase of amplification. The ratio
of GATA2 to BCR expression was determined after
densitometric analysis of the gels. GATA2 and BCR
amplifications were carried out with the same tem-
perature conditions described above. Primer se-
quences are shown in Table 2.
Rapid Amplification of cDNA Ends Polymerase
Chain Reaction
3-Rapid amplification of cDNA ends (RACE)
PCR was performed with a GeneRacer™ Kit (In-
vitrogen Life Technologies, Paisley, UK). Briefly,
first-strand cDNA was reversed-transcribed from 1
TABLE 1. Cytogenetics and Clinical Characteristics of the Patients Analyzed
Case
Age/
Sex Diagnosis Karyotype
BM
blasts
(%)
Hb
(g/dL)
Platelet
count
( 106/L)
Survival
(months)
1 65/M AML-M4 46,XY, inv(3)(q21q26)2[30] 49 10.6 167,000 24
2 57/M MDS (RAEB-2) 44,X,Y,inv(3)(q21q26),7[30] 12 9.6 531,000 14
3 27/F AML-M5a 46,XX,inv(3)(q21q26)[28]/46,XX[2] 47 7.3 624,000 11
4 55/F AML-M7 45,XX,inv(3)(q21q26),7[30] 39 11.7 260,000 5
5 54/M AML-M0 46,XY,t(1;7)(p32;p15),inv(3)(q21q26),
del(22)(q13)[36]/46,XY[14]
37 7.7 151,000 21
6 65/F MDS (RAEB-1) 46,XX,t(3;3)(q21;q26)[20] 6.5 7.5 195,000 Data not
available
7 69/M AML-M2 45,XY,t(2;7)(q21;q11),t(3;3)(q21;q26),del(5)(q13q33),
del(12)(p?11p13), del(13)(q13q34),
add(17)(p13),18,add(20)[18]/46,XY[2]
70 8.2 187,000 5
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Figure 1. (A) I. A map of the region from 3q21 to 3q26 showing the
relative positions of the clones used in this study and the genes involved.
A G-band pair of chromosome 3 is shown for a healthy donor and for
the cases analyzed. In each karyotype, normal chromosome 3 is shown
on the left and derivative chromosome 3 on the right, except for cases
1, 6, and 7, where both chromosomes are involved. II. FISH analysis with
probes RP11 390G14 (green signal) and RP11 475N22 (red signal). III.
FISH analysis with probes RP11 689D3 (green signal) and RP11 115B16
(red signal). (B) Interphase FISH analysis with probes RP11 475N22 (red
signal) and RP11 689D3 (green signal). Expected signal pattern when the
BP is (I) in RP11 475N22, (II) between RP11 475N22 and RP11 689D3,
and (III) in RP11 689D3.
g of total RNA using SuperScript™ II RNase H
RT (Invitrogen Life Technologies) and the Gen-
eRacer™ oligo-dT primer; 1 l of the first-strand
cDNA was then amplified by use of a GATA2 gene-
specific forward primer and the GeneRacer™ 3
primer. A seminested or nested PCR reaction was
performed using the GeneRacer™ 3 nested primer
as the reverse primer and a GATA2 gene-specific
forward primer. The gene-specific primers were
designed to cover all the possible breakpoints and
were used in pairs for the first and the second PCR
as follows: GATA2-ex1-F and GATA2 ex1-F,
GATA2-ex1-F and GATA2-ex2-F, GATA2-ex2-F
and GATA2-ex3-F, GATA2-ex3-F and GATA2-
ex5-F (Table 2). Amplifications were carried out
under standard conditions, at an AT of 64°C, and
for 35 cycles.
GATA1 Mutation Analysis
PCR was performed by use of genomic DNA
with primers GATA1-ex2-F and GATA1-ex2-R for
the analysis of exon 2 (Hitzler et al., 2003) and
primers GATA1-ex4-F and GATA1-ex4-R for the
analysis of exon 4 (Nichols et al., 2000) using a
standard protocol, an AT of 60°C, for 30 cycles.
Amplification products were directly sequenced af-
ter purification.
DNA Cloning and Sequencing
PCR products from the RT-PCR and the 3-
RACE experiments were cloned by use of the
TOPO TA Cloning Kit for Sequencing (Invitro-
gen Life Technologies). Colonies with recombi-
nant plasmids that contained the PCR products
were screened by digestion with EcoRI (Amersham
Biosciences, Buckinghamshire, UK). Candidate
plasmid clones and direct PCR products from the
mutation analysis of GATA1 were sequenced with
the ABI-PRISM™ d-Rhodamine Terminator Cycle
Sequencing Kit (Applied Biosystems) in an ABI
PRISM™ 377 DNA Sequencer (Applied Biosys-
tems).
RESULTS
We report here the molecular characterization of
the myeloid neoplasias and 3q21q26 rearrange-
ments of the seven patients who were studied. The
G-banded karyotype showed that five patients,
cases 1–5, had inv(3)(q21q26) and two patients,
cases 6 and 7, had translocation t(3;3)(q21;q26)
(Table 1). Six patients (cases 2–7) showed clinical
characteristics consistent with a 3q21q26 rearrange-
ment, including erythroid and megakaryocytic dys-
plasia, an elevated or normal platelet count, and a
TABLE 2. Oligonucleotide Primer Sequences*
Primer Oligonucleotide sequence (5–3) Gene Nucleotides
EVI1-F ACCCTTTGGCTAGATTATCTTAGACGA EVI1 63–89
EVI1-MDS1/EVI1-R CCAGCGAATCTAATGTACTTGAGC EVI1 167–144
MDS1/EVI1-F GGGCAGGACTAGGAATATGGAC MDS1/EVI1 2363–2384
MDS1-F GTGGGAGAGCAGAGGTCAAA MDS1 635–654
MDS1-R TCCCCAAATACAACCAAGAG MDS1 737–718
GR6-F CCCGGCCTGAGACAATGGAC GR6 30–49
GR6-R ACCCCCGAGTGTCTCTGGTG GR6 1153–1134
GATA-2-F AGGACGGCGTCAAGTACCAG GATA2 955–974
GATA-2-R CGCCATAAGGTGGTGGTTGT GATA2 1414–1395
BCR-F GAGAAGAGGGCGAACAAG BCR 2889–2906
BCR-R CTCTGCTTAATTCCAGTGGC BCR 3265–3246
GR6-1-F CCGGCCTGAGACAATGGA GR6 31–48
GR6-4-F GGCTGTCGGAATCAAAGAGG GR6 815–834
EVI1-2A-R TGGCATCTATGCAGAACTTCAC EVI1 121–100
RPN1-1-F CGCCGGCTTGTTTCTGCTC RPN1 152–170
EVI1-2B-R CCAGCGAATCTAATGTACTTGAGCC EVI1 167–143
GATA-2-ex1-F ATTGCCTGCCGCCACATCCATCCT GATA2 60–83
GATA-2-ex2-F CCGCGCAGCTGCTGCCTCCAGAC GATA2 439–461
GATA-2-ex3-F GGGGGACCGGCCTCCAGCTTCAC GATA2 1146–1168
GATA-2-ex5-F CCAGAAGAGCCGGCACCTGTTGT GATA2 1357–1379
GATA-1-ex2-F AAAGGAGGGAAGAGGAGCAG GATA1 4460–4479
GATA-1-ex2-R GACCTAGCCAAGGATCTCCA GATA1 4850–4831
GATA-1-ex4-F GAGGTGGGAGGGGTGGCCCAAAG GATA1 5699–5721
GATA-1-ex4-R CTGTAATCATGAGAACAGCGTTCC GATA1 6022–5999
*Nucleotide coordinates refer to GenBank mRNA accession numbers X54989 (EVI1), SG9002 (MDS1/EVI1), NM_004991 (MDS1), NM_007354 (GR6),
NM_032638 (GATA2), NM_004327 (BCR), and NM_002950 (RPN1). GATA1 coordinates refer to GenBank genomic accession number NM_002049.
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Figure 2. (A) Diagram showing the physical location of the probes
that cover the GATA2, GR6, and RPN1 genes on 3q21, from the Uni-
versity of Santa Cruz California Genome Bioinformatics Web site
(http://genome.ucsc.edu). (B) Positional relationship of the genes and
their transcriptional orientation in (I) normal chromosome 3, (II) case 1,
and (III) cases 2 and 3 (III) as a consequence of the rearrangement.
Vertical arrows indicate breakpoints.
poor prognosis. In case 1, neither multilineage in-
volvement nor megakaryocytic dysplasia was
found. Relevant clinical data are shown in Table 1.
FISH analysis helped to make a more precise
definition of the different BPs present in the 3q21
and 3q26 regions. Four BPs in 3q21 (BP-1, BP-2,
BP-3, and BP-4) and two in 3q26 (BP-5 and BP-6)
were defined (Fig. 1A). Case 1 showed an
inv(3)(q21q26) in both chromosomes 3 by G-band-
ing, which was more precisely defined using FISH.
Four BPs were found: BP-1 and BP-2 in 3q21 and
BP-5 and BP-6 in 3q26 (Fig. 1A). BP-2 was in RP11
475N22, which split. This BAC covers the GATA2
gene, in its centromeric region, and the GR6 gene,
in its telomeric region. Figure 2A shows the posi-
tion of the clones that cover genes GATA2, GR6,
and RPN1 in 3q21. The region between BP-5 and
BP-6 (3q26) contains genes EVI1 and MDS1 (Fig.
1A). Therefore, this patient had a complex rear-
rangement, with an insertion of a fragment from
3q21 into 3q26 and a second insertion of a fragment
from 3q26 located between BP-5 and BP-6 into the
3q21 region.
Cases 2 and 3 were the only ones sharing the
same BPs in 3q21 (BP-2) and 3q26 (BP-5). The
locations of the BPs indicate that the GR6 and
RPN1 genes, which came from 3q21, are adjacent
to EVI1 and MDS1 in 3q26, with their transcrip-
tional orientation changed as a consequence of the
inversion (Figs. 1A and 2B). In case 1, the same
BPs were also found; however, the presence of an
additional BP in each region led to a different final
gene orientation. In this case, it is the EVI1 and
MDS1 genes whose transcriptional sense has
changed and resulted in locations near and toward
GR6 and RPN1, but in the 3q21 region (Figs. 1A
and 2B).
Case 4 had two clones that differed in the loca-
tion of the 3q21 BP. Clone 4a had, as did case 5, a
BP in 3q21 between RP11 475N22 and RP11
689D3 (BP-3). In clone 4b, the BP in 3q21 was in
RP11 689D3, a BAC that covers RPN1 in its cen-
tromeric region (BP-4; Fig. 2A). In 3q26, BP-5 was
present in both clones of cases 4 and 5. In clone 4a
and case 5, GR6 remained in its original position,
whereas RPN1 changed its orientation and ap-
peared near to and oriented toward EVI1 and
MDS1 in 3q26 (Fig. 1A). In clone 4b, all of the
genes of interest remained in their original orien-
tation.
Cases 6 and 7 had a t(3;3)(q21;q26). The location
of the BPs in 3q26 was the same in both cases
(BP-6), whereas in 3q21 the BP was BP-2 in case 6,
but BP-1 in case 7 (Fig. 1A). The final position of
GATA2 in cases 1–3 and 6 is unknown. This is
because in these cases, BAC RP11 475N22, which
covers this gene, showed a split signal, but we did
not know whether the BP was upstream, down-
stream, or within the gene. All of these possibilities
were considered when we prepared Figure 2B.
We used RT-PCR to analyze the expression of
MDS1, MDS1/EVI1, EVI1, GR6, and GATA2 in BM
from the five patients with inv(3) and the one
patient with t(3;3) (case 7) and in BM, PB, and
CD34 from healthy donors (Fig. 3). No material
from case 6 was left for molecular studies. We
detected expression of MDS1/EVI1 and GATA2 in
normal BM but only expression of GATA2 in nor-
mal PB. In CD34 cells, expression of MDS1,
MDS1/EVI1, and EVI1 was detected, and there was
high expression of GATA2 compared with that in
normal BM (Fig. 3). No expression of GR6 was
found in normal BM, PB, or CD34 cells. Substan-
tial heterogeneity in the pattern of gene expression
in the cases analyzed was found (Fig. 3). Whereas
MDS1 was expressed only in case 3, MDS1/EVI1
expression was detected in all cases with variable
intensity (Fig. 3). Expression of EVI1 and GR6 was
detected only in case 2. Intergenic transcripts were
not detected between GR6 and EVI1 or between
RPN1 and EVI1 in any patients.
GATA2 expression was detected in all patient
samples with inv(3) and in the patient sample with
t(3;3). Compared with its expression in the BCR
control of normal BM, GATA2 seems to have been
overexpressed in cases 1, 2, 3, 5, and 7 (Fig. 3).
There was no material left from cases 1, 2, 3, and 5
for quantitative analysis. We designed a semiquan-
titative RT-PCR experiment to compare the ex-
pression of GATA2 in the BM of case 7 with its
expression in the BM of a healthy donor. Amplifi-
cation of BCR was used as an internal control. The
expression of GATA2 was 10 times higher in the
patient sample than in the control.
Because of the location of GATA2 beside the
breakpoint cluster region in 3q21 (BP-2), a possible
deregulation of this gene caused by its breakage
was investigated using 3-RACE PCR; however, no
new sequences fused to GATA2 in 3q26 were
found.
A recent study showed that GATA1 directly re-
presses GATA2, displacing the GATA2 protein
from its binding site and allowing cellular differen-
tiation. To check whether the dysfunction of
GATA1 could be the cause of the GATA2 overex-
pression, we analyzed the mutational status of ex-
ons 2 and 4 of GATA1 (Xp11). No mutations of
GATA1 were found in patients 2, 3, and 5. Patients
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2 and 5 were males. No material from cases 1 and
7 was available for these experiments.
We also designed a simple and efficient FISH
assay for the detection of all possible BPs in 3q21 in
patients with 3q21q26 rearrangements and for the
assignment of any BP found to either the break-
point cluster region telomeric (BCR-T) or break-
point cluster region centromeric (BCR-C), as pre-
viously reported (Wieser et al., 2000a). Our assay
consists of a unique experiment using only two
probes (RP11-475N22 and RP11 689D3) that cover
a region of 320 kb including both BCRs (Figs. 1B
and 2A). FISH analysis of eight cases with translo-
cations involving 3q21 other than inv(3) or t(3;3)
showed that in those cases, the BPs were outside
this region (data not shown).
DISCUSSION
The molecular characterization by FISH and
RT-PCR of five patients with inv(3)(q21q26) and
two patients with t(3;3)(q21;q26) showed wide het-
erogeneity in both the BPs and the expression
pattern of the genes near the BPs. FISH analysis
enabled a more precise definition of the BP in
these cases, providing data about the new posi-
tional relationship of the genes and the possible
implication for transcription derived from the rear-
rangements (Figs. 1A and 2B). Consideration of the
FISH and RT-PCR results together showed that
all of the cases were different. The only two cases
with the same BPs according to the FISH analysis
(cases 2 and 3) showed different expression pat-
terns. FISH analysis also allowed clarification of
the karyotype in case 1, resulting in a complex
ins(3)(q21q26) in both chromosomes 3. This sug-
gests that during the neoplastic process there was
duplication of the abnormal chromosome 3, with
loss of the normal chromosome 3.
In our study, we discriminated among the ex-
pression of the EVI1, MDS1, and MDS1/EVI1
genes. Surprisingly, expression of EVI1 was de-
tected only in one case (case 2). Even case 1, which
had two abnormal chromosomes 3, and case 3,
which shared with case 2 the same BPs in both
3q21 and 3q26, showed no expression of EVI1. The
lack of expression in these two cases suggests that
EVI1 overexpression is independent of 3q21q26
aberrations. Although EVI1 overexpression is a
common finding in 3q21q26 rearrangements
(Barjesteh van Waalwijk van Doorn-Khosrovani et
al., 2003; Martinelli et al., 2003; Vinatzer et al.,
2003), several studies have yielded other results.
Langabeer et al. (2001) detected no EVI1 expres-
sion in 3 of 19 patients with 3q26 rearrangements,
one of whom had an ins(3)(q26;q21q26) that could
be similar to our case 1. Morishita el al. (1992) also
reported no expression of EVI1 in seven patients
with inv(3), and additional cases with the same
characteristics have been described (Fichelson et
al., 1992; Soderholm et al., 1997). Although some of
these studies analyzed the transcript of cEVI1, a
region common to EVI1 and MDS1/EVI1, the neg-
ative result for both transcripts confirms the lack of
EVI1 expression. In addition, overexpression of
EVI1 was detected in 9% (28 of 315) of patients
who had AML but no 3q26 rearrangements
(Barjesteh van Waalwijk van Doorn-Khosrovani et
al., 2003), confirming that expression of this gene
cannot be considered a specific leukemogenic
mechanism for the 3q21q26 rearrangement. An-
other study on myeloid neoplasias showed the
same results, with a higher percentage of cases
without 3q21q26 rearrangements expressing EVI1
(7 of 34, 21%; Zoccola et al., 2003). Barjesteh van
Waalwijk van Doorn-Khosrovani et al. (2003)
showed that overexpression of EVI1, not of MDS1/
Figure 3. Analysis of the expression of MDS1,
MDS1/EVI1, EVI1, GR6, GATA2, and BCR in cDNA
from BM of cases 1–5 and 7 in CD34 cells, BM,
and PB from healthy donors.
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EVI1, was a poor prognosis factor in patients with
AML, independently of 3q26 rearrangements. In
our study, MDS1/EVI1 expression was detected in
normal BM, in CD34 cells, and in all patients
analyzed. Zoccola et al. (2003) reported the same
results. Putting these data together, it is possible to
affirm that both overexpression of EVI1 and
3q21q26 rearrangements are poor prognostic factors
in patients with myeloid neoplasias, although the
poor prognosis associated with 3q21q26 rearrange-
ments could be independent of EVI1 expression.
EVI1 is rarely involved in fusion transcripts in
3q21q26 rearrangements. RPN1–EVI1 has been re-
cently reported in 9 patients with AML with either
inv(3)(q21q26) or t(3;3)(q21;q26) (Martinelli et al.,
2003). Besides, the UCSD-AML1 cell line, with a
t(3;3), has both RPN1–EVI1 and GR6–EVI1 fusion
transcripts (Pekarsky et al., 1997). We found no ITs
in our cases. The position and the transcription
orientation of the genes involved as a consequence
of the rearrangements (Figs. 1A and 2B) make it
impossible for these ITs to occur in cases with
inv(3) (cases 2–5). In cases 6 and 7, which had a
t(3;3), ITs could arise. Only material from case 7
was available for analysis, and in the analysis, no
fusion transcripts were detected. Our results are
consistent with previous studies showing that over-
expression of EVI1 is unlikely to be a consequence
of the formation of fusion transcripts, which are not
a common finding in patients with 3q21q26 rear-
rangements (Pekarsky et al., 1997; Wieser, 2002).
Additional potential oncogenes in 3q21 and 3q26
are still under consideration (Russell et al., 1994;
Rynditch et al., 1997; Wieser, 2002). The sug-
gested role of RPN1 as an enhancer of EVI1 ex-
pression seems to be improbable because enhancer
elements in 3q21 have not yet been identified
(Rynditch et al., 1997; Wieser, 2002). Moreover,
the heterogeneity found by FISH in our series in
BP location and, in consequence, in the relative
position of the genes around them, makes a unique
mechanism improbable and adds support for the
hypothesis that there is a complex mechanism in-
volving several genes (Figs. 1A and 2B). The data
reported by Pekarsky and Rynditch suggest that
the 3q21 region is gene-rich and that additional
genes could be involved in these rearrangements
(Pekarsky et al., 1997; Rynditch et al., 1997). We
detected GR6 expression in a patient with
inv(3)(q21q26) (case 2), analyzing the most fre-
quent transcript, the splicing form from exon 1 to
exon 3 of GR6. The GR6 gene is downstream and
centromeric to RPN1, within the 3q21 BCR-T, and
is normally expressed in early fetal development
but not in adult tissues. GR6 was first found to be
activated in the UCSD-AML1 cell line and in a
leukemic sample, both carrying a t(3;3)(q21;q26)
(Pekarsky et al., 1997). Recently, GR6 expression
also was reported in nine patients with AML and
3q21q26 rearrangements (Martinelli et al., 2003).
However, the low incidence of GR6 ectopic expres-
sion suggests that this cannot be considered a gen-
eral mechanism for rearrangements in 3q21, al-
though a role in a more complex mechanism cannot
be refuted completely.
Interestingly, GATA2 expression was detected in
all patients. Although a quantitative analysis was
not possible in all patients because of limited ma-
terial, a comparison with the BCR control suggests
that GATA2 was overexpressed in patients 1, 2, 3, 5,
and 7, when compared with normal BM (Fig. 3).
This was confirmed by semiquantitative RT-PCR
in case 7, which showed an expression of GATA2 10
times higher in the patient with t(3;3) than in the
controls (data not shown). Wieser et al. (2000b)
reported that GATA2 was overexpressed in 7 of 9
patients with myeloid neoplasias and 3q21 rear-
rangements, suggesting that, in these cases, the
leukemogenic mechanism could be GATA2 dereg-
ulation. GATA2 is one of the six members of the
GATA family of zinc finger transcription factors,
which are characterized by the ability to bind the
consensus DNA sequence WGATAR (Orkin,
1992). Among these genes, GATA1, GATA2, and
GATA3 play crucial roles in hematopoiesis. GATA1
is highly expressed in erythroid cells and
megakaryocytes (Tsai et al., 1989) and is required
for terminal differentiation of these lineages (Si-
mon et al., 1992; Tsang et al., 1998). GATA2 is
highly expressed in hematopoietic stem and pro-
genitor cells, and its expression dramatically de-
creases when erythroid and megakaryocytic differ-
entiation proceeds (Tsai et al., 1994, 1997; Cantor
et al., 2002). A recent study showed that GATA1
directly represses GATA2 by a bimodal mechanism.
First, the binding of GATA1 to a region 2.8 kb
upstream of GATA2 displaces the GATA2 protein
from this location, repressing GATA2 transcription.
Second, GATA1 also displaces the histone acetyl-
transferase CREB-binding protein (CBP), leading
to the establishment of a domain-wide repressive
chromatin structure. Such mechanisms seem to be
critical for the control of hematopoietic differenti-
ation (Grass et al., 2003) and could have particular
relevance in 3q21q26 rearrangement, which is char-
acterized by dysplasia of the erythroid and
megakaryocytic lineages. Therefore, GATA2 could
be a candidate gene in 3q21. Moreover, all of the
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BPs in 3q21 reported so far were upstream of the
coding region of GATA2. It has been reported that
in mice, properly regulated hematopoietic expres-
sion of Gata2 depended on the presence of at least
150 kb of upstream sequences; if this observation
could be extrapolated to the human gene, GATA2
would be disrupted in all the 3q21 BPs described to
date (Wieser, 2002). According to the current map-
ping data, GATA2 is in RP11 475N22, the BAC that
was split in three of our cases (cases 1, 2, and 3),
with overexpression of GATA2.
To determine whether the breakpoint was within
GATA2 and whether this was the cause of the dereg-
ulation of this gene, we performed a 3RACE PCR
assay. However, no new sequences in 3q26 fused to
GATA2 were found. Similarly, Wieser et al. (2000b)
found no structural aberrations of GATA2 in the cell
lines analyzed by Southern blotting. To study
whether the loss of function of GATA1 could be the
cause of GATA2 overexpression, we analyzed exons 2
and 4 of GATA1, looking for possible mutations.
Wechsler et al. (2002) reported mutations in exon 2 of
GATA1 that led to a shorter GATA1 protein with
reduced transactivation activity, potentially affecting
normal megakaryocytic differentiation in children
with Down syndrome and a megakaryoblastic AML
(M6). On the other hand, hemizygotic mutations in
exon 4 of GATA1 (Xp11) have also been reported to
cause congenital defects in males, including dyser-
ythropoietic anemia, because of the substitution of a
highly conserved valine, which is necessary for the
interaction of GATA1 with its essential cofactor
FOG-1, underscoring the importance of GATA1 in
both megakaryocyte and erythroid development (Ni-
chols et al., 2000). We detected no mutations of
GATA1, either in exon 2 or in exon 4, in patients 2, 3,
and 5, thus excluding this mechanism as well. Pa-
tients 2 and 5 were males; thus, they had only one
GATA1 allele.
The poor prognosis that characterizes patients
with 3q21q26 rearrangements makes it important
to discriminate among the mechanisms involved in
order to design useful stratified treatment ap-
proaches.
Finally, this study has allowed us to design a
simple and efficient FISH assay for the detection
of all possible BPs in 3q21 in patients with 3q21q26
rearrangements and to assign these BPs to the
BCR-T or BCR-C defined by Wieser et al. (2000a).
Our assay consists of a unique experiment using
only two probes that cover a 320-kb region includ-
ing both BCRs. This assay simplified the design
reported by Wieser et al. (2001), which used six
BACs for the BCR-C and five BACs for the BCR-T
in two separate experiments.
In conclusion, this is the first report of molecular
heterogeneity in cases with 3q21q26 rearrange-
ments both in the BPs in these regions and in the
expression pattern of the genes near the BPs. The
breakpoints in 3q21 and 3q26 were defined by
FISH, providing data about the new positional re-
lationship of the genes. The different expression
pattern of the genes around the breakpoints con-
firmed this heterogeneity. EVI1 expression was
found in only one patient, suggesting that overex-
pression of this gene is a mechanism that fails to
explain the characteristics of all these cases. These
results argue for the hypothesis that the ectopic
expression of EVI1 directed by RPN1 acting as an
enhancer is unlikely to be the sole molecular mech-
anism in patients with 3q21q26 rearrangements
and that there is a complex mechanism involving
several genes. GATA2, which was overexpressed in
83% of our cases, might have a role in this putative
complex mechanism that should be elucidated.
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